MNCs Need China-Oriented Oncology Strategy Mixed With Pricing Know-how
This article was originally published in PharmAsia News
Executive Summary
To succeed in China's fast-growing oncology market, multinational pharma companies need to look closely at their product mix and figure out whether getting listed on the country's reimbursed drug list will increase volume enough to offset price reductions, or whether it makes more sense to charge full retail prices to patients paying out-of-pocket and settle for lower volume
You may also be interested in...
Dynamic Markets Need Dynamic Pricing: Roche Explores Differential Pricing Strategies In Emerging Markets
Roche experiments with a variety of tactics, including second brands, patient assistant programs, supporting private insurance and other ways to drive volume in highly fragmented markets.
Lacking Guidelines, HER2 Testing Brings Challenges To Breast Cancer Treatment In China
In a recent report, Kantar Health takes a deep dive into China’s breast cancer market, where cost considerations play a larger role than in the West.
Lacking Guidelines, HER2 Testing Brings Challenges To Breast Cancer Treatment In China
In a recent report, Kantar Health takes a deep dive into China’s breast cancer market, where cost considerations play a larger role than in the West.